Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Familial hypercholesterolemia patients can benefit from alirocumab drug

Familial hypercholesterolemia patients can benefit from alirocumab drug

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Amgen, Novartis collaborate for Alzheimer's disease and migraine programs

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Bionomics submission of BNC101 IND for cancer treatment passes FDA review

Continuous therapy improves multiple myeloma outcomes

Continuous therapy improves multiple myeloma outcomes

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

iCo Therapeutics incurs total comprehensive loss of $738,607 for second quarter 2015

Antiviral-based therapies have potential to protect humans from deadly Ebola virus

Antiviral-based therapies have potential to protect humans from deadly Ebola virus

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

European chestnut leaves contain ingredients with power to disarm deadly staph bacteria

European chestnut leaves contain ingredients with power to disarm deadly staph bacteria

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Risk for endophthalmitis no higher with Avastin, finds study

Risk for endophthalmitis no higher with Avastin, finds study

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

CMC Biologics, PATH Malaria Vaccine Initiative sign agreement for development of specific monoclonal antibodies

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Janssen signs license agreement with Alligator Bioscience for immuno-oncology antibody

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

CRI announces winners of 2015 Oliver R. Grace Award for Distinguished Service in Advancing Cancer Research

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Penn Medicine devises new approach to develop vaccines against lethal diseases

Penn Medicine devises new approach to develop vaccines against lethal diseases

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.